Clinical Trials Browser

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

37 enrolled 8 charts

Breast

Triple Negative Breast Neoplasms

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1 Recruiting

43 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Breast

Triple Negative Breast Neoplasms

NCT06690840 2026-01-05

AZALEA

Phase 2 Recruiting

45 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast

Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

Phase 3 Completed

184 enrolled 15 charts

Breast

Triple Negative Breast Neoplasms

NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Phase 2 Active not recruiting

37 enrolled

Breast

Inflammatory Breast Neoplasms

NCT03483012 2025-12-09

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Phase 2 Active not recruiting

6 enrolled 19 charts

Breast

Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

33 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01898117 2025-11-26

Triple-B

Phase 2 Active not recruiting

304 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02849496 2025-11-24

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Phase 2 Active not recruiting

81 enrolled

Breast

Breast Neoplasms

NCT03371017 2025-11-12

IMpassion132

Phase 3 Completed

595 enrolled 37 charts

Breast

Triple Negative Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast

Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04273061 2025-09-22

CAPTIV-8

Phase 2 Recruiting

200 enrolled

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasms, Unknown Primary, Sarcoma, Skin Neoplasms, Urogenital Neoplasms

NCT03802604 2025-09-09

PROMETEO

Phase EARLY_PHASE1 Completed

28 enrolled

Breast

Breast Neoplasms

NCT04759248 2025-09-09

ATREZZO

Phase 2 Active not recruiting

55 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

914 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

220 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04740918 2025-08-08

KATE3

Phase 3 Terminated

96 enrolled 16 charts

Breast

Breast Neoplasms

NCT03289962 2025-07-04

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Phase 1 Completed

272 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06067061 2025-06-11

neoBREASTIM

Phase 1/2 Terminated

2 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03417544 2025-04-02

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Phase 2 Active not recruiting

19 enrolled 26 charts

BreastCNS

HER2-positive Metastatic Breast Cancer

NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Phase 1/2 Terminated

222 enrolled 49 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05332561 2025-03-20